CorMedix (CRMD)
(Delayed Data from NSDQ)
$5.31 USD
+0.12 (2.31%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $5.30 -0.01 (-0.19%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
CRMD 5.31 +0.12(2.31%)
Will CRMD be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CRMD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CRMD
Wall Street Analysts Predict a 146.21% Upside in CorMedix (CRMD): Here's What You Should Know
Here's Why CorMedix (CRMD) Looks Ripe for Bottom Fishing
CRMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
How Much Upside is Left in CorMedix (CRMD)? Wall Street Analysts Think 198.21%
Cidara Therapeutics (CDTX) Reports Q4 Loss, Misses Revenue Estimates
Pliant Therapeutics, Inc. (PLRX) Reports Q4 Loss, Tops Revenue Estimates
Other News for CRMD
CorMedix Inc. Announces CMS Grants TDAPA to DefenCath
CorMedix announce CMA granted TDAPA to DefenCath
CVAC, SBNY and CRMD are among after hour movers
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin)